Zogenix plans to conduct public offering of 3.8 million common shares

Company also cancels at-the-market equity deal with Cantor Fitzgerald

By Devika Patel

Knoxville, Tenn., July 28 – Zogenix, Inc. will sell 3.8 million common shares in a public sale with a 30-day greenshoe of 570,000 additional shares, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission. The company also terminated an at-the-market equity offering with agent Cantor Fitzgerald & Co.

Leerink Partners LLC and Stifel, Nicolaus & Co. Inc. are the bookrunners for the public offering.

The deal is expected to settle in August.

Proceeds will be used for clinical research and development, commercial activities, working capital and other general corporate purposes.

The company also cancelled its at-the-market equity offering with Cantor Fitzgerald on July 28, according to an 8-K filing with the SEC. The deal was arranged on Nov. 6.

San Diego-based Zogenix is a pharmaceutical company focused on medicines to treat central nervous system disorders and pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.